A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

NCT05292898 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Achieve the proof of concept

Conditions

Acute Lymphocytic Leukemia

Interventions

BIOLOGICAL: LCAR-AIO Cells

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

[object Object]